References
- Zhang X, Sun J, Yang M, et al. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm. Crit Rev Oncol Hematol. 2020;149:102928.
- Sapienza MR, Abate F, Melle F, et al. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica. 2019;104(4):729–737.
- Menezes J, Acquadro F, Wiseman M, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28(4):823–829.
- Wang L, Yang M, Zhang X, et al. ARID1A mutation in blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2017;102(11):e470–e472.
- Feng Y, Li X, Cassady K, et al. TET2 function in hematopoietic malignancies, immune regulation, and DNA repair. Front Oncol. 2019;9:210.
- Jin MH, Oh DY. ATM in DNA repair in cancer. Pharmacol Ther. 2019;203:107391.